Princess Ghida Talal։ Our Heartfelt Thanks to Everyone Who Believed in Our Mission and Stood by Our Patients / cancer, ...

Mocertatug Rezetecan Shows 62% Response Rate in Platinum-Resistant Ovarian Cancer / Antibody drug conjugates, B7-H4, BEHOLD-1 ...

Torvutatug Samrotecan Shows 56.6% Response Rate in Platinum-Resistant Ovarian Cancer / Antibody drug conjugates, AZD5335, ...

FOURLIGHT-1 shows atirmociclib plus fulvestrant improved PFS to 9.4 vs 6.6 months after prior CDK4/6 inhibition in HR+/HER2− ...

Three ESMO 2026 Themes Shaping Geriatric Oncology / cancer, esmo 2026, ESMO26, Geriatric Oncology, Nicolò Matteo Luca ...

FRα-Targeted ADC Shows 58% Response Rate in Platinum-Resistant Ovarian Cancer / ADC therapy, Antibody drug conjugates, cancer ...

Closing the Invisible Middle Between Cancer Prevention and Care / cancer, cancer care, Cancer Prevention, Miriam Mutebi, ...

Different Meetings, Same Passion for Oncology, Leadership, and Advocacy! / Abirami Sivapiragasam, American Society of ...

Key Insights From ESMO 2026 / advanced NSCLC, BMS symposium, cancer, ESMO26, immunotherapy, KRAS Lung Cancer, Lung cancer, ...

Improving Clinical Trial Access Through Health Literacy and Patient Support / cancer, cancer care, Joanna Metzner-Sadurski, ...

NATALEE shows adjuvant ribociclib reduced mortality by 19%, with 6-year OS of 91.9% vs 89.7% in HR+/HER2− early breast cancer ...

Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research / ...